Devyser Diagnostics AB

Equities

DVYSR

SE0016588867

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:24:44 2024-05-02 am EDT			5-day change	1st Jan Change
99.4 ^SEK	+0.61%		-4.42%	+26.46%

Apr. 25	Devyser Receives IVDR Approval for Post-Transplant Monitoring Software	CI
Mar. 11	Devyser Diagnostics AB Achieves Breakthrough in the US with Cystic Fibrosis NGS Test	CI

Devyser Genomic Laboratories Signs First Commercial Agreement with Cyted

January 17, 2024 at 05:30 am EST

Devyser Genomic Laboratories has signed its first commercial agreement with Cyted. The initial period for the agreement is two years with estimated total revenue amounting up to approximately SEK 25 Million where of approximately up to SEK 6 million in 2024.

Latest news about Devyser Diagnostics AB

Devyser Receives IVDR Approval for Post-Transplant Monitoring Software	Apr. 25	CI
Devyser Diagnostics AB Achieves Breakthrough in the US with Cystic Fibrosis NGS Test	Mar. 11	CI
Devyser Diagnostics AB Announces Study Publication Demonstrating dd-cfDNA Detection in Dual Donor Kidney Transplant Patient	Feb. 29	CI
Transcript : Devyser Diagnostics AB, Q4 2023 Earnings Call, Feb 20, 2024	Feb. 20
Devyser Diagnostics AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 20	CI
Devyser Diagnostics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 19	CI
Devyser Diagnostics AB Announces Michael Uhlin, CSO Joins Management Team as of February 1, 2024	Jan. 29	CI
Devyser's US Lab Inks SEK25 Million Deal with UK Diagnostics Company Cyted	Jan. 17	MT
Devyser Genomic Laboratories Signs First Commercial Agreement with Cyted	Jan. 17	CI
Sweden’s Devyser Wins SEK1.5 Million Tender in Italy for Cystic Fibrosis Test Kits	Jan. 15	MT
Devyser Diagnostics AB Wins Tender for Cystic Fibrosis in Italy	Jan. 15	CI
Devyser Diagnostics Teams Up with Illumina to Offer IVD Tests in Europe, US	Jan. 08	MT
Devyser Diagnostics AB Signs in Vitro Diagnostic Agreement with Illumina to Broaden Access to Its Tests	Jan. 08	CI
Sweden’s Devyser Wins $6 Million Tender for Cystic Fibrosis Diagnostic Tool in Italy	Dec. 11	MT
Devyser Wins Approximately SEK 2 Million Tender for Cystic Fibrosis	Dec. 11	CI
Devyser Diagnostics Bags Non-invasive Fetal RHD Test Tender in Wales	Dec. 05	MT
Devyser wins tender for non-invasive fetal RHD testing in Wales	Dec. 05	CI
Transcript : Devyser Diagnostics AB, Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Devyser Diagnostics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Devyser and Thermo Fisher Scientific Collaborate to Promote Laboratory Services to Advance Pharmaceutical Research	23-09-13	CI
Thermo Fisher Scientific to Sell Devyser Diagnostics' Transplantation Products in Brazil	23-09-06	MT
Devyser and Thermo Fisher Scientific Expand the Collaboration for Post-Transplant Ngs Products by Adding Brazil	23-09-06	CI
Transcript : Devyser Diagnostics AB, Q2 2023 Earnings Call, Aug 23, 2023	23-08-23
Devyser Diagnostics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-23	CI
Devyser's Ngs Products for Monitoring of Kidney and Stem Cell Transplanted Patients Receive IVDR Approvals	23-07-17	CI

Chart Devyser Diagnostics AB

Duration

Period

More charts

Company Profile

Devyser Diagnostics AB is a Sweden-based company engaged in development, manufacture ad sale of kits for genetic testing in routing diagnostic to laboratories. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The company has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnosticsâ products are sold directly to the end customer or through hired distributors. The Company provides its products in more than 45 countries.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Devyser Diagnostics AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

62.75 DKK

Average target price

82.33 DKK

Spread / Average Target

+31.20%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
DEVYSER DIAGNOSTICS AB	+26.46%	147M
MODERNA, INC.	+27.63%	42.68B
IQVIA HOLDINGS INC.	-3.08%	42.4B
LONZA GROUP AG	+45.32%	40.04B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+6.80%	24.94B
ALNYLAM PHARMACEUTICALS, INC.	-21.20%	18.96B
MEDPACE HOLDINGS, INC.	+28.54%	12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.48%	11.95B
BIO-TECHNE CORPORATION	-1.79%	11.55B

Other Biotechnology & Medical Research